Cullinan Therapeutics, Inc.
CGEM
$16.33
$0.181.12%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 52.28M | 54.25M | 56.49M | 56.21M | 55.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 240.35M | 241.65M | 241.44M | 234.70M | 208.93M |
| Operating Income | -240.35M | -241.65M | -241.44M | -234.70M | -208.93M |
| Income Before Tax | -221.04M | -219.88M | -216.70M | -206.65M | -178.62M |
| Income Tax Expenses | -- | -- | 117.00K | 117.00K | 117.00K |
| Earnings from Continuing Operations | -221.04 | -219.88 | -216.81 | -206.76 | -178.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 0.00 | 0.00 | 0.00 |
| Net Income | -221.04M | -219.88M | -216.81M | -206.76M | -178.74M |
| EBIT | -240.35M | -241.65M | -241.44M | -234.70M | -208.93M |
| EBITDA | -240.04M | -241.34M | -241.13M | -234.39M | -208.62M |
| EPS Basic | -3.72 | -3.72 | -3.68 | -3.52 | -3.10 |
| Normalized Basic EPS | -2.33 | -2.33 | -2.30 | -2.20 | -1.93 |
| EPS Diluted | -3.72 | -3.72 | -3.68 | -3.52 | -3.10 |
| Normalized Diluted EPS | -2.33 | -2.33 | -2.30 | -2.20 | -1.93 |
| Average Basic Shares Outstanding | 237.75M | 236.20M | 235.58M | 234.84M | 230.87M |
| Average Diluted Shares Outstanding | 237.75M | 236.20M | 235.58M | 234.84M | 230.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |